The effects Of sodium-glucose coTransporter 2 inhibiTOR on fastIng Hepatic Insulin Clearance in type 2 diabetes
Not Applicable
Not yet recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-jRCT1061230070
- Lead Sponsor
- Okura Tsuyoshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Type 2 diabetes
2. HbA1c 6.5~10%
3. Diet therapy only, or Metformin, or DPP4 inhibitor
Exclusion Criteria
1) Type 1 diabetes
2) Severe ketosis, diabetic coma within the past 24 weeks
3) Severe infection, operation, severe trauma
4) Pregnancy
5) Severe liver dysfunction
6) Severe renal dysfunction
7) Highper sensitivity to SGLT2 inhibitor
8) Urinary tract infection, genital infection
9) Malignancy
10) Administration history of SGLT2 inhibitor within 24 weeks
11) Administration history of insulin injection or sulfonylurea within 24 weeks
12) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method